Trastuzumab for HER2-positive metastatic breast cancer: Clinical and economic considerations

Alwin Jeyakumar, Tallal Younis

Research output: Contribution to journalReview articlepeer-review

23 Citations (Scopus)


Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extra-cellular domain of the HER2 receptor. It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and has since led to significant improvements in the overall prognosis for patients with HER2-positive metastatic disease. The favourable benefit/risk profile associated with palliative trastuzumab has been demonstrated in a number of clinical trials that examined trastusumab as monotherapy or in combination with chemotherapy, endocrine therapy and other HER2 targeted agents. The clinical benefits of trastuzumab, however should also be examined within the context of its significant drug acquisition costs. This review highlights the significant findings from the landmark clinical trials of trastuzumab for metastatic HER2-positive breast cancer, and the potential "value for money" associated with its use in clinical practice.

Original languageEnglish
Pages (from-to)179-187
Number of pages9
JournalClinical Medicine Insights: Oncology
Publication statusPublished - 2012
Externally publishedYes


  • Breast cancer
  • Clinical trials
  • Cost-effectiveness analysis
  • Economics
  • HER2-positive
  • Palliative
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Trastuzumab for HER2-positive metastatic breast cancer: Clinical and economic considerations'. Together they form a unique fingerprint.

Cite this